Displaying drugs 11301 - 11325 of 11951 in total
Ponazuril
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Vet approved
Matched Description: … Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for …
(5E,7E,9)-decatrien-2-one
An compound produced by Fomitopsis betulina, an edible fungus commonly called the birch polypore. Similar to (5Z,7E,9)-decatrien-2-one, it has a strong pineapple aroma.
Experimental
Matched Description: … Similar to [(5Z,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116] …
(5Z,7E,9)-decatrien-2-one
An compound produced by Fomitopsis betulina, an edible fungus commonly called the birch polypore. Similar to (5E,7E,9)-decatrien-2-one, it has a strong pineapple aroma.
Experimental
Matched Description: … Similar to [(5E,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116] …
2'-Fucosyllactose
2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Investigational
Matched Description: … Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a …
HTPEP-001
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Matched Description: … HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta …
Dazostinag
Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent …
Survodutide
Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)).
Investigational
Matched Description: … Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide …
Ephedra sinica stem
Experimental
Laromustine
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia …
Befunolol
Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Experimental
Matched Description: … Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. …
Tandamine
Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Experimental
Matched Description: … Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI). …
HX-1171
Hx 1171 is under investigation in clinical trial NCT01548391 (A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects).
Investigational
Matched Description: … Hx 1171 is under investigation in clinical trial NCT01548391 (A Phase I Clinical Study Study of the Safety …
PF-05089771
PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).
Investigational
Matched Description: … PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of …
Tavapadon
Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).
Investigational
Matched Description: … Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability …
PCS-499
PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).
Investigational
Matched Description: … PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety …
Human Lactoferrin Peptide hLF1-11
Human Lactoferrin Peptide hLF1-11 is under investigation in clinical trial NCT00509834 (A Study on the Tolerability and Early Efficacy of Hlf1-11 in Patients With Proven Candidaemia).
Investigational
Matched Description: … Human Lactoferrin Peptide hLF1-11 is under investigation in clinical trial NCT00509834 (A Study on the …
Zampilimab
Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury).
Investigational
Matched Description: … Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability …
Utidelone
Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.
Investigational
Matched Description: … Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic …
Bacteroides thetaiotaomicron
Bacteroides thetaiotaomicron is a live biotherapeutic. Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.
Investigational
Matched Description: … Bacteroides thetaiotaomicron is a live biotherapeutic. …
Volixibat
Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH.
Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational
Matched Description: … Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane ... Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for ... granted fast track status by the Food and Drug Administration due to promising initial results and a …
Meclocycline
Meclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) .
Investigational
Idronoxil
Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
Investigational
Matched Description: … Idronoxil is a substance that is being studied in the treatment of cancer. …
Cefilavancin
Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.
Investigational
Matched Description: … Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that …
Glembatumumab vedotin
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Investigational
Matched Description: … A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E …
MLN2222
MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.
Investigational
Matched Description: … MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which …
Displaying drugs 11301 - 11325 of 11951 in total